Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

SCI Pharmacovigilance: neurologic drug safety in spinal cord injury

Funder: Craig H Neilsen Foundation

Funding period
USD 297 K
Funding amount
Abstract
Traumatic spinal cord injury is caused by sudden mechanical trauma to the spinal cord, resulting in mild to severe paralysis and reduced sensation. In addition to paralysis and sensory loss, acute spinal cord injury is accompanied by various other complications (eg. neuropathic pain, blood pressure irregularities, infections, spasticity), which are managed with a variety of classes of medications. Our recent review of the acute pharmacological management of spinal cord injury revealed that individuals received up to 58 unique medications over the first 3 months post injury. Despite this ‘extreme polypharmacy’, the ‘neurologic safety’ (i.e., effects on residual muscle strength) of administering medications, alone or in combination, in the acute phases of injury has received very little attention. This is surprising considering that many medications are centrally acting and their administration overlaps with recovery of neurological function. Moreover, patients and their caregivers have urgent questions with regards to factors that potentially interfere with their recovery. At present, care providers cannot provide an informed, evidence-based response regarding the use of commonly used medications (alone or in combination) in the acute phase of spinal cord injury. The primary objective of our study is therefore to determine the neurologic safety of acutely administered medications following spinal cord injury. In doing so, we will also establish a pharmacovigilance platform to report, visualize, and analyze neurologic drug safety in the field of spinal cord injury. (CHN: SCIRTS chn:wdg)
Similar projects All >
Sorted by: Start Date
Project list item
Single-Cell Transcriptome and Epigenome of Regenerating CST Neurons

Craig H Neilsen Foundation to Jae Mun Kim, Binhai Zheng

USD 150,000
2020 - 2022
Project list item
Activating dI3 interneurons to promote recovery of locomotor function

Craig H Neilsen Foundation to Tuan Vu Bui, Alex Laliberte, Iroshan Hewage, Sara Goltash

USD 300,000
2020 - 2022
Project list item
The role of lipid dysfunction in spinal cord injury pathophysiology

Craig H Neilsen Foundation to John Carib Gensel, Alan Daugherty, Katherine Thompson, Kevin Hatton

USD 599,000
2020 - 2023
Project list item
Age-dependent decline of axon growth via reduction of SOCS3/STAT3 signaling

Craig H Neilsen Foundation to Cédric G Geoffroy, Alexandra Lopez, Phillip West, Theresa Sutherland

USD 300,000
2020 - 2022
Project list item
Chemogenetic Silencing of Interneurons to Modulate Autonomic Dysreflexia

Craig H Neilsen Foundation to Felicia Mary Michael, George Smith, Samirkumar Patel, Xiao-Ming Xu

USD 150,000
2020 - 2022

System

Categories
  • FOR (ANZSRC)

    1103 Clinical Sciences

  • FOR (ANZSRC)

    1109 Neurosciences

  • RCDC

    Injury (total) Accidents/Adverse Effects

  • RCDC

    Injury - Trauma - (Head and Spine)

  • RCDC

    Regenerative Medicine

  • RCDC

    Neurosciences

  • RCDC

    Pain Research

  • RCDC

    Chronic Pain

  • RCDC

    Spinal Cord Injury

  • RCDC

    Neurodegenerative

  • RCDC

    Patient Safety

  • HRCS HC

    Neurological

  • HRCS HC

    Injuries and Accidents

  • HRCS RAC

    6.1 Pharmaceuticals

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science